



Australian Government

Department of Health  
Therapeutic Goods Administration

# Advisory Committee on Medicines

Meeting Statement 10 - Thursday 2 August 2018

## Section A: Submissions for registration

The committee's advice was sought on seven new pre-market applications for prescription medicines, as tabulated below.

Number of applications	Application Type	Main consideration by ACM
7	Type A - New Chemical /Biological Entities/Biosimilar	For general consideration

Further details of the ACM discussions and advice associated with pre-market items are released within the Australian Public Assessment Reports (AusPARs) for each new active. Please note that there is a delay from when an application was considered at ACM, and the publication of the AusPAR. [Browse all AusPARs](#).

## Section B: Post-market items referred for advice

No pharmacovigilance items were discussed.

## Further information

For further information on the ACM, please visit [Advisory Committee on Medicines](#) or contact the ACM Secretary by email [ACM@health.gov.au](mailto:ACM@health.gov.au).